Development and automation of a novel NET-PET tracer: [11C]Me@APPI

Nuclear Medicine and Biology

Volumn 40, Issue 2, 2013, Pages 295-303

  Mark, Christina ^a,b   Bornatowicz, Birgit ^b   Mitterhauser, Markus ^a,c   Hendl, Matthias ^a   Nics, Lukas ^a,b   Haeusler, Daniela ^a   Lanzenberger, Rupert ^a   Berger, Michael L ^d   Spreitzer, Helmut ^b   Wadsak, Wolfgang ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d Medical University of Vienna   (Austria)

Author keywords

Carbon 11; Me@APPI; Noradrenaline; PET; Radiosynthesis; Transporter

Indexed keywords

1 [3 (METHYLAMINO) 1 PHENYLPROPYL] 3 PHENYL 1H BENZO[D]IMIDAZOL 2(3H)ONE C 11; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG PENETRATION; DRUG PURIFICATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOACTIVITY;

AUTOMATION; BENZIMIDAZOLES; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; DRUG STABILITY; HUMANS; ISOTOPE LABELING; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOCHEMISTRY;

EID: 84872893422     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.11.009     Document Type: Article

References (34)

1. Zhou J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 2004, 29:1235-1244.
2. Klimek V., Stockmeier C.A., Overholser J., Meltzer H.Y., Kalka S., Dilley G., et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997, 17:8451-8458.
3. Ressler K.J., Nemeroff C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999, 46:1219-1233.
4. Ordway G.A., Stockmeier C.A., Cason G.W., Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci 1997, 17:1710-1719.
5. Gulyás B, Brockschnieder D, Nag S, Pavlova E, Kása P, Beliczai Z, et al. The norepinephrine transporter (NET) radioligand (S, S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: A post-mortem autoradiographic study. Neurochem Int 56:789-98.
6. Mash D.C., Ouyang Q., Qin Y., Pablo J. Norepinephrine transporter immunoblotting and radioligand binding in cocaine abusers. J Neurosci Methods 2005, 143:79-85.
7. Smith H.R., Beveridge T.J.R., Porrino L.J. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience 2006, 138:703-714.
8. Logan J., Wang G.-j., Telang F., Fowler J.S., Alexoff D., Zabroski J., et al. Imaging the norepinephrine transporter in humans with (S, S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol 2007, 34:667-679.
9. Donnan G.A., Kaczmarczyk S.J., Paxinos G., Chilco P.J., Kalnins R.M., Woodhouse D.G., et al. Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography. J Comp Neurol 1991, 304:419-434.
10. Halldin C., Farde L., Högberg T., Mohell N., Hall H., Suhara T., et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995, 36:1275-1281.
11. Fowler J.S., Volkow N.D., Wang G.J., Gatley S.J., Logan J. [11C]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001, 28:561-572.
12. Pristupa Z.B., Wilson J.M., Hoffman B.J., Kish S.J., Niznik H.B. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol 1994, 45:125-135.
13. Tejani-Butt S.M. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 1992, 260:427-436.
14. Bock N., Quentin D.J., Hüther G., Moll G.H., Banaschewski T., Rothenberger A. Very early treatment with fluoxetine and reboxetine causing long-lasting change of the serotonin but not the noradrenaline transporter in the frontal cortex of rats. World J Biol Psychiatry 2005, 6:107-112.
15. Wilson A.A., Patrick Johnson D., Mozley D., Hussey D., Ginovart N., Nobrega J., et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 2003, 30:85-92.
16. Takano A., Gulyás B., Varrone A., Halldin C. Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S, S)-[18F]FMeNER-D2; and (S, S)-[11C]MeNER. Eur J Nucl Med Mol Imaging 2009, 36:1885-1891.
17. Schou M., Halldin C., Sóvágó J., Pike V.W., Hall H., Gulyás B., et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004, 53:57-67.
18. Schou M., Zoghbi S., Shetty H., Shchukin E., Liow J.-S., Hong J., et al. Investigation of the metabolites of (S, S)-[11C]MeNER in humans, monkeys and rats. Mol Imaging Biol 2009, 11:23-30.
19. Zhang P., Terefenko E.A., McComas C.C., Mahaney P.E., Vu A., Trybulski E., et al. Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett 2008, 18:6067-6070.
20. Varney M., Romines W., Boritzki T., Margosiak S., Bartlett C., Howland E. Syntheses and biological evaluation of N-[4-(2-trans-[([2,6-diamino-4(3H)-oxopyrimidin-5-YL]methyl)thio]cyclobutyl)benzoyl]-L-glutamatic acid a novel 5-thiapyrimidone inhibitor of dihadrofolate-reductase. J Heterocycl Chem 1995, 32:1493-1498.
21. Jona H., Shibata J., Asai M., Goto Y., Arai S., Nakajima S., et al. Efficient and practical asymmetric synthesis of 1-tert-butyl 3-methyl (3R,4R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-1,3-dicarboxylate, a useful intermediate for the synthesis of nociceptin antagonists. Tetrahedron: Asymmetry 2009, 20:2439-2446.
22. Larsen P., Ulin J., Dahlstrøm K., Jensen M. Synthesis of [11C]iodomethane by iodination of [11C]methane. Appl Radiat Isot 1997, 48:153-157.
23. Kniess T., Rode K., Wuest F. Practical experiences with the synthesis of [11C]CH3I through gas phase iodination reaction using a TRACERlabFXC synthesis module. Appl Radiat Isot 2008, 66:482-488.
24. Jewett D.M. A simple synthesis of [11C]methyl triflate. International Journal of Radiation Applications and Instrumentation. Part A. Appl Radiat Isot 1992, 43:1383-1385.
25. Radioactive pharmaceuticals (Radiopharmaceutica, 6.0/0125), European Pharmacopoeia (Europäisches Arzneibuch): Verlag Österreich GmbH; 2008, p. 995 ff.
26. Zeng F., Jarkas N., Owens M.J., Kilts C.D., Nemeroff C.B., Goodman M.M. Synthesis and monoamine transporter affinity of front bridged tricyclic 3β-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2β-position. Bioorg Med Chem Lett 2006, 16:4661-4663.
27. Donovan S.F., Pescatore M.C. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecyl-poly(vinyl alcohol) high-performance liquid chromatography columns. J Chromatogr A 2002, 952:47-61.
28. Naik P., Cucullo L. In vitro blood-brain barrier models: current and perspective technologies. J Pharm Sci 2012, 101:1337-1354.
29. Neuhaus W., Freidl M., Szkokan P., Berger M., Wirth M., Winkler J., et al. Effects of NMDA receptor modulators on a blood-brain barrier in vitro model. Brain Res 2011, 1394:49-61.
30. Tavares A.A., Lewsey J., Dewar D., Pimlott S.L. Radiotracer properties determined by high performance liquid chromatography: a potential tool for brain radiotracer discovery. Nucl Med Biol 2012, 39:127-135.
31. Nics L., Vraka C., Hendl M., Haeusler D., Wagner K.-H., Shanab K., et al. In-vitro stability of [18F]FE@SUPPY and [18F]FE@SUPPY:2 against human liver-microsomes and human plasma. Nuklearmed-Nucl Med 2011, 50:A176.
32. Någren K., Halldin C., Pike V.W., Allonen T., Hietala J., Swahn C.G., et al. Radioactive metabolites of the 5-HT1A receptor pet radioligand, [carbonyl-11C]way-100635, measured in human plasma samples. J Label Compd Radiopharm 2001, 44:S472-S474.
33. Parsey R.V., Ojha A., Ogden R.T., Erlandsson K., Kumar D., Landgrebe M., et al. Metabolite considerations in the in vivo quantification of serotonin transporters using 11C-DASB and PET in humans. J Nucl Med 2006, 47:1796-1802.
34. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., Houle S. Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter[colon] modeling strategies. J Cereb Blood Flow Metab 2001, 21:1342-1353.